Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
By P. Aisen, K. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K. Davis, M. Farlow, Shelia Jin, Ronald G. Thomas, L. Thal. Journal of the American Medical Association (JAMA), 2003
964 citations recorded by the source corpus.
Subfields: Pharmacology, Physiology
View Paper: https://www.semanticscholar.org/paper/763f6821468f023e0d47af8bda642cff647e2684
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
In Physiology
- Ronald C. Petersen
- Clifford R. Jack Jr.
- P. Aisen
- David A. Bennett
- J. Morillas-Ruiz
- J. M. Rubio-Pérez
- S. Rivest
- Sokratis G. Papageorgiou
Citations in the corpus
- Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. (2004, methodology): “We therefore included in these analyses patients recently recruited to an ADCS clinical trial.(25) We included patients with AD who had a global CDR of 0.”
- Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. (2006, background): “Some also argue that NSAIDs have no effect in patients suspected to have already developed AD (Aisen et al., 2003) and that treatment with a cyclooxygenase-2 inhibitor increases the amount of b-amyloid found in the brain (Kukar et al., 2005).”
- Current and future treatments for Alzheimer’s disease (2013, result): “Despite this premise, prospective studies showed lack of efficacy [Aisen et al. 2002, 2003] or treatmentlimiting gastrointestinal toxicity [Rogers et al. 1993].”
- Mechanisms Underlying Inflammation in Neurodegeneration (2010, neutral): “, 2009), but clinical trials of these agents in patients with manifest disease have failed in AD (Aisen et al., 2003; Reines et al., 2004) and ALS (Cudkowicz et al.”
- A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines (2012, background): “A randomized, double-blind, placebo-controlled trial assessing the effect of the COX-2 inhibitor rofecoxib and the COX-1 and COX2 inhibitor naproxen versus placebo on AD progression did not slow the cognitive decline of patients with mildto-moderate AD [191].”